Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Glenmark Pharmaceuticals (NSE:GLENMARK) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Glenmark Pharmaceuticals Forward PE Ratio Related Terms
Glenmark Pharmaceuticals Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glenmark Pharmaceuticals Forward PE Ratio Chart
Glenmark Pharmaceuticals Annual Data
Trend
2018-03
2019-03
2020-03
2025-03
2026-03
Forward PE Ratio
16.64
19.23
5.96
24.74
26.33
Glenmark Pharmaceuticals Quarterly Data
2018-03
2018-06
2018-09
2018-12
2019-03
2019-06
2019-09
2019-12
2020-03
2020-06
2020-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
2026-06
Forward PE Ratio
16.64
18.76
21.01
20.62
19.23
12.47
12.24
10.42
5.96
13.97
14.27
25.13
24.74
28.14
30.87
24.51
26.33
26.16
NSE:GLENMARK vs ZTS: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glenmark Pharmaceuticals Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Glenmark Pharmaceuticals's Forward PE Ratio falls into.
Glenmark Pharmaceuticals Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Glenmark Pharmaceuticals (NSE:GLENMARK) has a Forward PE Ratio of 31.01 as of Sep. 03, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Glenmark Pharmaceuticals and its competitors. According to the industry distribution chart, Glenmark Pharmaceuticals ranks #330 out of 412 companies in the Drug Manufacturers industry, placing it in the top 80.1%.
Is Glenmark Pharmaceuticals' Forward PE Ratio too high?
Glenmark Pharmaceuticals' current Forward PE Ratio is 31.01. The Drug Manufacturers industry median Forward PE Ratio is 14.81. Glenmark Pharmaceuticals' value of 31.01 is 109.5% above this industry median. Based on the distribution chart, Glenmark Pharmaceuticals ranks #330 out of 412 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Glenmark Pharmaceuticals has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glenmark Pharmaceuticals' Forward PE Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Glenmark Pharmaceuticals ranks #330 out of 412 companies for Forward PE Ratio. This places Glenmark Pharmaceuticals in the lower half of its industry. The industry median Forward PE Ratio is 14.81. Glenmark Pharmaceuticals' value of 31.01 is 109.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 14.81, based on 412 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Glenmark Pharmaceuticals's current Forward PE Ratio of 31.01 is 109.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Glenmark Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 14.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glenmark Pharmaceuticals's current Forward PE Ratio is 31.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glenmark Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals (NSE:GLENMARK) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,188.90, compared to a current price of ₹2,460.00 — trading 12.4% above its estimated fair value. The current Forward PE Ratio is 31.01 and 109.5% above the Drug Manufacturers industry median of 14.81. Glenmark Pharmaceuticals' overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Glenmark Pharmaceuticals (NSE:GLENMARK), the current Forward PE Ratio is 31.01 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glenmark Pharmaceuticals (NSE:GLENMARK) Overvalued in 2026?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹2,460.00 is trading 12.4% above its estimated GF Value™ of ₹2,188.90.
GuruFocus considers Glenmark Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for NSE:GLENMARK:
Forward PE Ratio: 31.01
GF Value™: ₹2,188.90 vs. price of ₹2,460.00 (12.4% above fair value)
Industry Position: 109.5% above the Drug Manufacturers median (#330 of 412)
No single metric tells the full story. See the NSE:GLENMARK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
85GF Score
Get the complete analysis for NSE:GLENMARK
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLENMARK has been successfully added to your 
